Clinical trial
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
NCT00580840
Study timeline
Study start (unknown)2007-12-01Date precision: month
Registry last updated2018-08-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Rheumatoid Arthritisunresolved
Interventions
Certolizumab pegolDRUG · verified · RxNorm: certolizumab pegol
Certolizumab pegolDRUG · verified · RxNorm: certolizumab pegol
PlaceboOTHER
Sponsors & collaborators
UCB Pharmalead sponsor
Mapped research locations
Los AngelesCalifornia, United States1DallasTexas, United States1TorontoOntario, Canada1San AntonioTexas, United States1ParisFrance1ClevelandOhio, United States1San DiegoCalifornia, United States1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1Las VegasNevada, United States1RochesterMinnesota, United States1CharlotteNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00580840 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.